0001193125-26-155057
SEC filingCryo-Cell reported a modest revenue decline and significantly reduced profitability in Q1 FY2026, driven by elevated litigation-related expenses under the Duke arbitration, while gross margin remained stable and free cash flow was preserved through disciplined capital allocation.
Cryo-Cell’s Q1 FY2026 financial performance reflects continued execution against core operational priorities amid heightened legal activity. Revenue of $7.7M represents a 3.6% decline from $8.0M in Q1 FY2025. The Company attributes revenue trends to broader market conditions, noting in its business context that ‘a vast majority of expectant parents are simply unaware that umbilical cord blood contains a rich supply of non-controversial stem cells’ — a structural awareness challenge that shapes demand formation over time. Referral-based growth remains foundational, as management states revenues ‘have been facilitated by a variety of referral sources, resulting from high levels of customer satisfaction.’